For the Inventor, By the Inventor

Enter assignee name

Tübingen, Germany

Curevac Ag

USPTO Granted Patents = 96

CIPO Patents = 87

EPO Patents = 61

Trademarks = 16

Forward Citations = 2,778

Loading Chart...

Loading Chart...

82 inventors (with patents filed for the assignee):

Jochen Probst (29 out of 37 patents)

Andreas Thess (25 out of 66 patents)

Thomas Schlake (22 out of 32 patents)

4. Karl-Josef Kallen (20 out of 29 patents)

5. Mariola Fotin-Mleczek (19 out of 26 patents)

6. Ingmar Hoerr (16 out of 21 patents)

7. Benjamin Petsch (14 out of 42 patents)

8. Thomas Kramps (12 out of 25 patents)

9. Patrick Baumhof (12 out of 20 patents)

10. Margit Schnee (11 out of 21 patents)

11. Steve Pascolo (11 out of 24 patents)

12. Florian Von Der Mülbe (10 out of 20 patents)

13. Tilmann Roos (7 out of 18 patents)

14. Benyamin Yazdan Panah (7 out of 14 patents)

15. Thomas Ketterer (7 out of 25 patents)

Core Competencies:

Long-Chain RNA

Nucleic Acid Cargo

Coronavirus Vaccine

RNA Therapeutics

Combination Vaccines

Stabilised mRNA

Immunostimulating Agents

RNA Encoding Proteins

Artificial Nucleic Acids

Tumor Treatment

Vaccine Development

Inhibition of PD-1 Pathway

96 patents: Sort by Forward Citations

1. 11534405 - Dry powder composition comprising long-chain RNA (2022-12-27),

2. 11478552 - Hybrid carriers for nucleic acid cargo (2022-10-25),

3. 11471525 - Coronavirus vaccine (2022-10-18),

4. 11464847 - Lassa virus vaccine (2022-10-11),

5. 11464836 - RNA for treatment or prophylaxis of a liver disease (2022-10-11),

6. 11458195 - Combination of vaccination and inhibition of the PD-1 pathway (2022-10-04),

7. 11458193 - Combination of vaccination and inhibition of MHC class I restricted antigen presentation (2022-10-04),

8. 11433027 - Dry powder composition comprising long-chain RNA (2022-09-06),

9. 11421038 - RNA-coded antibody (2022-08-23),

10. 11413346 - Rotavirus vaccines (2022-08-16),

11. 11384375 - Immobilized poly(n)polymerase (2022-07-12),

12. 11369694 - Rabies vaccine (2022-06-28),

13. 11369691 - Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions (2022-06-28),

14. 11345920 - Artificial nucleic acid molecules for improved protein expression (2022-05-31),

15. 11286492 - Artificial nucleic acid molecules for improved protein expression (2022-03-29),

CureVac AG is a leading clinical-stage biopharmaceutical company dedicated to developing fully optimized mRNA-based vaccines and therapeutics for the prevention and treatment of infectious diseases and cancer. The company's proprietary messenger RNA (mRNA) technology platform allows for the development of personalized medicines, targeting a wide range of diseases, and has attracted collaborations with major pharmaceutical companies. CureVac is headquartered in Tübingen, Germany.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

96 Patents

#1 in Tübingen

#646 in Germany

#7,807 in the World

Tübingen, Germany

Curevac Ag

Forward Citations = 2,778

82 inventors:

Jochen Probst (29 out of 37 patents)

Andreas Thess (25 out of 66 patents)

Thomas Schlake (22 out of 32 patents)

4. Karl-Josef Kallen (20 out of 29 patents)

5. Mariola Fotin-Mleczek (19 out of 26 patents)

Please report any incorrect information to support@idiyas.com

Loading…